Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Standard
Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight. / Svane, Maria S.; Johannesen, Helle H.; Hansen, Adam E.; Martinussen, Christoffer; Bojsen-Møller, Kirstine N.; Hansen, Martin Lundsgaard; Deacon, Carolyn F.; Keller, Sune H.; Klausen, Thomas L.; Loft, Annika; Kjaer, Andreas; Löfgren, Johan; Madsbad, Sten; Holst, Jens J.; Wewer Albrechtsen, Nicolai J.
I: International Journal of Obesity, Bind 46, Nr. 11, 2022, s. 2058–2062.Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight
AU - Svane, Maria S.
AU - Johannesen, Helle H.
AU - Hansen, Adam E.
AU - Martinussen, Christoffer
AU - Bojsen-Møller, Kirstine N.
AU - Hansen, Martin Lundsgaard
AU - Deacon, Carolyn F.
AU - Keller, Sune H.
AU - Klausen, Thomas L.
AU - Loft, Annika
AU - Kjaer, Andreas
AU - Löfgren, Johan
AU - Madsbad, Sten
AU - Holst, Jens J.
AU - Wewer Albrechtsen, Nicolai J.
N1 - Publisher Copyright: © 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022
Y1 - 2022
N2 - We investigated the effect of pharmacologically induced weight loss on markers of glucagon resistance in individuals with overweight during treatment with the glucagon-like peptide-1 receptor agonist liraglutide. We performed an open-label study in 14 men with overweight (age 38 ± 11 years, BMI 32 ± 4 kg/m2) without simultaneously diabetes. Subjects were treated with liraglutide, initiated and titrated with 0.6 mg/day/week to reach the final dose of 3.0 mg/day. Subjects were examined at baseline, during titration (Week 4), after 2 weeks of steady state (Week 6) of final dosing of liraglutide and 3 weeks after discontinuation of liraglutide (follow-up). Study participants lost 3.3 ± 1.9 kg (3%) total body weight during the first 4 weeks of treatment with liraglutide. Simultaneously, liver fat content decreased from 12.4 ± 11.6% to 10.2 ± 11.1%, p = 0.025, whereas fat content in the spleen and subcutaneous tissue was unaltered. Markers of glucagon resistance, including plasma glucagon and the glucagon-alanine-index, also decreased significantly during treatment, but total and individual plasma amino acid concentrations did not. Insulin resistance (HOMA-IR) was unchanged during treatment, whereas insulin clearance increased. Treatment with the GLP-1 receptor analogue liraglutide decreased liver fat content, and simultaneously attenuated glucagon concentrations and the glucagon-alanine index in individuals with overweight without diabetes.
AB - We investigated the effect of pharmacologically induced weight loss on markers of glucagon resistance in individuals with overweight during treatment with the glucagon-like peptide-1 receptor agonist liraglutide. We performed an open-label study in 14 men with overweight (age 38 ± 11 years, BMI 32 ± 4 kg/m2) without simultaneously diabetes. Subjects were treated with liraglutide, initiated and titrated with 0.6 mg/day/week to reach the final dose of 3.0 mg/day. Subjects were examined at baseline, during titration (Week 4), after 2 weeks of steady state (Week 6) of final dosing of liraglutide and 3 weeks after discontinuation of liraglutide (follow-up). Study participants lost 3.3 ± 1.9 kg (3%) total body weight during the first 4 weeks of treatment with liraglutide. Simultaneously, liver fat content decreased from 12.4 ± 11.6% to 10.2 ± 11.1%, p = 0.025, whereas fat content in the spleen and subcutaneous tissue was unaltered. Markers of glucagon resistance, including plasma glucagon and the glucagon-alanine-index, also decreased significantly during treatment, but total and individual plasma amino acid concentrations did not. Insulin resistance (HOMA-IR) was unchanged during treatment, whereas insulin clearance increased. Treatment with the GLP-1 receptor analogue liraglutide decreased liver fat content, and simultaneously attenuated glucagon concentrations and the glucagon-alanine index in individuals with overweight without diabetes.
U2 - 10.1038/s41366-022-01207-y
DO - 10.1038/s41366-022-01207-y
M3 - Letter
C2 - 35982119
AN - SCOPUS:85136243978
VL - 46
SP - 2058
EP - 2062
JO - International Journal of Obesity
JF - International Journal of Obesity
SN - 0307-0565
IS - 11
ER -
ID: 318444360